iShares Global Govt Bond UCITS ETF EUR Hedged (Dist) (IGLEa)

Overview

Alphamab Oncology is a pioneering clinical stage biopharmaceutical company rooted in the heart of Suzhou, the People's Republic of China. Founded in the year 2008, the firm has dedicated itself to the noble cause of fighting cancer through the discovery, development, manufacture, and commercialization of innovative oncology biologics. Alphamab Oncology stands at the frontier of creating a new era in cancer treatment, focusing on offering groundbreaking solutions that promise to redefine the standards of care in oncology.

Products and Services

KN046: A cutting-edge bispecific monoclonal antibody (BsAb) serving as an immune checkpoint inhibitor. Currently in Phase III clinical trials, KN046 effectively targets and inhibits two crucial immune checkpoints: programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This dual blockade mechanism presents a novel approach in the immunotherapy landscape for cancer treatment.

KN026: Representing the next generation in antibody precision, KN026 is an anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody. It is undergoing Phase II clinical trials, focusing on the neoadjuvant treatment of HER2-positive breast cancer and the treatment of heavily pre-treated breast cancers. Furthermore, KN026 is in Phase II clinical trials for HER2-positive solid tumors, showcasing its versatility and potential in targeting HER2-mediated cancers.

KN019: This CTLA-4-based immunosuppressant fusion protein is exploring new frontiers in Phase II clinical trials by targeting auto-immune diseases and oncology treatment-induced immune disorders. KN019’s mechanism seeks to modulate the immune system’s response, offering new hope in the treatment of complex auto-immune conditions and the adverse effects arising from cancer therapies.

KN035: A promising injectable PD-L1 inhibitor in phase III clinical trials for patients with advanced solid tumors presenting with deficient mismatch repair/microsatellite instability-high. KN035 is also being evaluated in Phase III studies for its potential in treating biliary tract cancer, underlining its significance in targeting PD-L1 as a mechanism to combat advanced stages of cancer.

KN052: A PD-L1/OX40 bispecific antibody currently in phase I clinical trial. KN052 aims to treat advanced solid tumors by synergizing the blockade of PD-L1 with the stimulation of the OX40 pathway, a novel approach expected to enhance the antitumor immune response.

JSKN003: A biparatopic HER2-targeting antibody-drug conjugate in phase Ia/Ib clinical trial for the treatment of advanced malignant solid tumors. JSKN003 encapsulates the innovative strategy of combining targeted therapy with chemotherapy, promising a potent mechanism against HER2-positive cancers by delivering cytotoxic agents directly to cancer cells.